PepMed 2026: What to Expect from the Peptide Medicine Congress in Washington, 17 to 18 September

PepMed 2026 is a two-day peptide medicine congress on 17 and 18 September 2026 at the Four Seasons Hotel, 2800 Pennsylvania Avenue NW, Washington, DC. The organiser is the American Academy of Peptide Medicine (AAPM), a non-profit founded in 2025, and the event is billed as the first annual "Regenerative Health World Congress" under the theme "Advancing the Science, Policy, and Practice of Peptide Therapeutics". This is a preview written in the first week of September 2026 from the published programme; the Bureau will update this page after the event with what was actually said.

The timing is the reason it matters. The congress falls eight weeks after the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for the 503A bulks list, and before the FDA has published any proposed rule. The opening session on the Thursday morning is literally titled "The Vote and What Follows". For researchers, compounders and vendors trying to read where the regulatory line will be drawn in 2027, this is the room where the people drawing it will be talking.

Who is behind it

AAPM describes itself as "the official nonprofit academic society dedicated to advancing the responsible clinical use of peptide therapies". Its about page names two leaders: Lee Rosebush, PharmD, JD, MBA, as Chairman and Chief Pharmacy Officer, and Dr Pradeep Albert, MD, as Chief Medical Officer. The organisation says it works on three pillars, policy advocacy, professional education and credentialing, and safety standards for compounding pharmacies and clinical protocols, and that it has catalogued 174 peptides. Its homepage says the founding advisory board includes "former governors from both Republican and Democratic administrations", which matches the two ex-governors on the Thursday agenda.

AAPM also runs a "PepMed" certification programme, a five-module curriculum with an exam, and says CME and CPE partnerships are planned. For the congress itself the site states: "Continuing education credit is not yet available and is pending accreditation." Clinicians attending for credit should check that line again closer to the date.

The Bureau has no relationship with AAPM and has not been offered or accepted a press pass. This preview is built from the public congress site, the AAPM site and one clinician's published preview, all listed in the sources.

Venue, dates, price and format

Everything in this section is as stated on congress2026.pepmed.org in the first week of September 2026.

• Dates: Thursday 17 and Friday 18 September 2026.
• Venue: Four Seasons Hotel, 2800 Pennsylvania Ave NW, Washington, DC 20007.
• Format: "20+ sessions" across four pillars: Science, Policy, Practice, Community. Day 1 runs from 8:00 AM registration to a 6:00 PM reception. Day 2 is listed as "In Development, Subject to Change" with a Day 2 Only pass available.
• Price: "$200 to $1,000 by registration type", with "Full 2-day access, all sessions, meals included".
• Sponsors named: Ivím Health, Enhanced Games and MuseCell Innovations, each attached to a sponsored session.
• Credit: pending accreditation, not yet available.

The programme page carries the line "Tentative program. Sessions and times are subject to change, and additional speakers will be announced as they are confirmed." Treat every time below as provisional.

The Day 1 agenda, session by session

The published Thursday programme is dense: sixteen sessions, one keynote and a reception in ten hours. The table below is the Bureau's condensed version with the named speakers as listed. Titles and affiliations are the organiser's.

Day 2, Friday 18 September, is listed as in development with state regulation and closing remarks flagged as themes. The Bureau will fill it in if the organiser publishes it before the event.

What to expect: the four sessions that matter for the research market

The Vote and What Follows (8:55). Timothy Fensky is on the panel for The Peptide Council, and the pharmacy voices later in the day are the people who would actually compound BPC-157 or TB-500 if the FDA adds them to the list. Expect a clear account of what compounders think the proposed rule will say and how long they expect it to take. The Bureau's own summary of the July result, with every tally, is on the PCAC vote page. What the room will not be able to say is when the FDA will publish; the estimates the Bureau has seen run from eight months to more than a year.

What's Next for Compounding: From Bulks List to Bench (2:15). Three compounding pharmacies on one panel. The questions a researcher should listen for are about specification: the FDA's own scientists told PCAC that for some of these peptides there is no accepted chemical identity to compound against. Whatever standard the pharmacies say they will use for BPC-157 acetate or TB-500 is the standard that testing labs serving the research market will eventually be measured against. The peptide testing guide explains why that gap exists today.

Bringing the Molecule Home (3:00). Domestic manufacturing is the supply-chain question underneath everything else. Almost all bulk research peptide currently originates overseas; a congressman is moderating a panel with an analytical lab (ARL) and a manufacturer. If a US GMP source for compounding-grade peptide emerges, it changes the cost and the paperwork for everyone downstream.

Reach and Responsibility (1:40). Ben Greenfield and Gary Brecka are on a panel about marketing peptides to the public. Given that the FDA's warning letters through 2026 have turned on how vendors and telehealth firms describe their products, the line between education and drug promotion is not academic. The vendor shutdown tracker lists the letters issued so far this year.

Why it matters, and what it is not

PepMed 2026 is a policy and practice congress, not a scientific meeting. There is no abstract programme, no poster session and no peer-reviewed proceedings. The speaker list is weighted to clinic operators, compounders, telehealth executives, elected officials and advocates, with HHS represented by an Assistant Secretary and a senior adviser. Dr Steven Murphy, a longevity clinician who says he will attend, described the programme in a 2 September 2026 post as including "peptide clinicians, compounding pharmacists, analytical testing experts, policy figures, legal experts, digital-health executives, researchers, and government participants", and argued that the field has to move "from the gray market" toward standardised practice. That is a fair description of what the event is for.

It is also, in a quieter way, the first public gathering of the coalition that got twelve peptides out of Category 2 in April and six of them through PCAC in July. Anyone who wants to understand why the FDA's own reviewers were overruled by a committee vote will hear the argument made at length. Anyone who wants the counter-argument should read the STAT and Health Affairs coverage of the July meeting instead, because it is not on the programme.

For a researcher, the practical reasons to watch are three. First, the compounding specification question, which will eventually define what a "pure" BPC-157 vial means. Second, the domestic manufacturing question, which will define where it comes from and what it costs; the peptide therapy cost guide shows how far compounded and research prices already diverge. Third, the state regulation session on both days, since state pharmacy boards and medical boards are where clinics actually get disciplined, whatever the federal list says.

The same week, Murphy's post also repeated a point that matters for a different set of readers: the FDA's current GLP-1 compounding guidance states that retatrutide and cagrilintide cannot be used in compounding under federal law, since neither is an approved drug component or on the 503A list. No session on the programme is going to change that. The compounded retatrutide page covers the position.

How to follow it if you are not in Washington

The organiser has not announced a livestream on the pages the Bureau fetched; one session (Gary Brecka's) is marked virtual for the speaker, not for the audience. Registration ranges from $200 to $1,000 and includes meals; the Day 2 Only pass is the cheapest way in. If you are attending, the two sessions to take notes in are the 2:15 compounding panel and the 3:00 manufacturing panel, because those are the ones whose content will show up in vendor COAs and price lists over the next year.

The Bureau will publish a post-event summary on this page in the week of 21 September 2026, covering what the compounders said about specifications and timelines, whether HHS gave any date for a proposed rule, and anything said about research-use-only sales. Until then the pre-event facts above are all that is verifiable. If you are running a protocol in the meantime, the arithmetic has not changed: the reconstitution calculator and the BPC-157 guide are where to start. Nothing here is medical advice; these are research compounds and the Bureau does not advise anyone on using them.

Frequently Asked Questions

When and where is PepMed 2026?

PepMed 2026, subtitled the Regenerative Health World Congress, runs Thursday 17 and Friday 18 September 2026 at the Four Seasons Hotel, 2800 Pennsylvania Avenue NW, Washington, DC. The organiser is the American Academy of Peptide Medicine, a non-profit founded in 2025 and chaired by Lee Rosebush, PharmD, JD. The congress site lists more than 20 sessions across science, policy, practice and community, with Day 1 running from 8:00 AM registration to a 6:00 PM reception and Day 2 still listed as in development when the Bureau checked.

Who is speaking at PepMed 2026?

The published Day 1 programme names more than fifty people. Government participants include Admiral Brian Christine, Assistant Secretary for Health at HHS, HHS senior adviser Calley Means, and Representatives Diana Harshbarger, Rich McCormick and Eli Crane. Compounding is represented by Timothy Fensky of The Peptide Council, Shawn Hodges of Revelation Pharma, Jay Bhaumik of Thesis Pharmacy and Nate Hill and Matt Montes de Oca of Strive Pharmacy. Clinicians include Dr Alex Tatem, Dr Jessica Duncan and Dr Terri DeNeui. Ben Greenfield and Gary Brecka appear on a marketing panel. All are as listed by the organiser.

How much does PepMed 2026 cost?

The congress site states $200 to $1,000 depending on registration type, with full two-day access, all sessions and meals included at the top tier, and a Day 2 Only pass available. The Bureau did not see early-bird deadlines or member discounts on the pages it fetched. Continuing education credit is described as not yet available and pending accreditation, so clinicians attending for CME or CPE should confirm that before paying. Prices and terms are the organiser's and may change; check congress2026.pepmed.org for the current figures.

Is PepMed a scientific conference?

Not in the academic sense. There is no abstract call, poster session or peer-reviewed proceedings on the published programme. It is a policy and practice congress whose speakers are mainly clinic operators, compounding pharmacists, telehealth executives, elected officials, advocates and HHS officials. The sessions most relevant to the science are the compounding panel on specifications, the domestic manufacturing panel with an analytical laboratory, and the women's health evidence-gap session. Researchers looking for new data should treat it as a regulatory briefing rather than a data release.

Why does PepMed 2026 matter for research peptide buyers?

Because it is the first public meeting of the compounding and clinic coalition after the July 2026 PCAC vote and before any FDA proposed rule. What the compounders say about chemical specifications for BPC-157 and TB-500 will eventually set the reference standard testing labs use. What the manufacturing panel says about US production will shape supply and price. And what HHS officials say, or decline to say, about timing is the best available signal on when the bulks-list rulemaking will move. None of it changes the legal status of research-use-only sales, which remain subject to FDA warning letters.

Will the Bureau cover what was said at PepMed 2026?

Yes. This page is a preview built from the published programme, the AAPM site and one clinician's preview post, all fetched in the first week of September 2026. The Bureau plans to update it in the week of 21 September with a post-event summary covering the compounding specification discussion, any timeline given for the 503A rulemaking, the domestic manufacturing panel and anything said about research-use-only vendors. Until then, treat every session title and speaker as provisional; the organiser marks the programme as tentative and subject to change.

Research use only. The compounds discussed are sold as research chemicals and are not approved for human use. Nothing here is medical advice.